Sex differences in efficacy/safety of anti-amyloid-beta monoclonal antibodies for the treatment of Alzheimer's disease. — Alzheimer's disease (AD) is the most common cause of dementia. AD exhibits notable sex-related disparities in prevalence, progression, and treatment response. With the recent approval of...

Evidence span

Sex differences in efficacy/safety of anti-amyloid-beta monoclonal antibodies for the treatment of Alzheimer's disease. — Alzheimer's disease (AD) is the most common cause of dementia. AD exhibits notable sex-related disparities in prevalence, progression, and treatment response. With the recent approval of...

From Lim S et al. 2025, Translational and clinical pharmacology

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

source-reported model organism

Conditions

— Translational and clinical pharmacology 2025

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required